Peptidylprolyl Isomerase A Pseudogene 35 as a Drug Target and Biomarker: An Overview

Target Name: PPIAP35

NCBI ID: G128192

PPIAP35

Other Name(s): peptidylprolyl isomerase A pseudogene 35 | LOC128192 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene

Peptidylprolyl Isomerase A Pseudogene 35 as a Drug Target and Biomarker: An Overview

Peptidylprolyl isomerase A (PPIAP35) is a protein that plays a crucial role in the regulation of protein synthesis in the cell. It is a member of the peptidyl-prolyl isomerase family 35, which is responsible for the conversion of prolyl-phosphate (P-P) to prolyl-isocaproic acid (P-Ic). PPIAP35 is expressed in various tissues and cells, including the brain, heart, and gastrointestinal tract, and its function is highly conserved across species.

Despite its importance in cellular signaling, PPIAP35 has not yet been explored as a drug target or biomarker. The identification of PPIAP35 as a potential drug target would have significant implications for the development of new therapeutics for various diseases, including neurodegenerative disorders, pain, and inflammation.

PPIAP35 as a Drug Target

The identification of PPIAP35 as a potential drug target is based on several factors. Firstly, PPIAP35 has been shown to play a role in the regulation of protein synthesis, which is a key step in the development and progression of many diseases. Secondly, PPIAP35 is a versatile enzyme, as it can be used as a probiotic to promote protein synthesis in the gut microbiota, making it an attractive candidate for therapeutic applications in fields such as dietary supplements and probiotics.

PPIAP35 has been shown to play a role in the development and progression of several diseases, including neurodegenerative disorders, pain, and inflammation. For instance, PPIAP35 has been associated with the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as it is involved in the regulation of the build-up of beta-amyloid peptides in the brain.

In addition to its involvement in neurodegenerative disorders, PPIAP35 has also been shown to play a role in the regulation of pain and inflammation. For example, PPIAP35 has been shown to reduce pain perception in animal models of pain, and it has been shown to protect against inflammation in various experimental models of inflammation.

Biomarker Potential

The discovery of PPIAP35 as a potential drug target also has significant implications for the development of new biomarkers for various diseases. PPIAP35 is expressed in various tissues and cells, including the brain, heart, and gastrointestinal tract, making it an attractive candidate for use as a biomarker for a wide range of diseases.

For example, PPIAP35 has been shown to be highly expressed in the brain, making it an attractive candidate for use as a biomarker for neurodegenerative disorders. Additionally, PPIAP35 has been shown to be involved in the regulation of protein synthesis, which could be used as a biomarker for various diseases associated with protein synthesis disruption, such as cancer, cardiovascular disease, and dietary deficiencies.

Conclusion

In conclusion, PPIAP35 is a protein that has not yet been fully explored as a drug target or biomarker. The identification of PPIAP35 as a potential drug target and biomarker has significant implications for the development of new therapeutics for various diseases. Further research is needed to fully understand the role of PPIAP35 in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Peptidylprolyl Isomerase A Pseudogene 35

The "PPIAP35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets